There are currently 65 clinical trials in Webster, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Center for Clinical Studies, Tranquil Clinical Research, Center for Clinical Studies, LTD. LLP and Center of Reproductive Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Patient Retrospective Outcomes (PRO)
NCT01550575
Recruiting
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Space City Pain Specialists, Webster, Texas
Conditions: Chronic Pain
Register for Updates
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612
Recruiting
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Tranquil Clinical Research, Webster, Texas
Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Register for Updates
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379
Recruiting
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Research Site, Webster, Texas
Conditions: Breast Cancer
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients
NCT05899608
Recruiting
This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer. The primary endpoint is overall survival and key secondary endpoints include progression free survival. response and safety.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Summit Therapeutics Research Center, Webster, Texas
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Phase III Study of AK112 for NSCLC Patients
NCT06396065
Recruiting
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Texas Oncology Webster, Webster, Texas
Conditions: Non-Squamous Non-small Cell Lung Cancer
Register for Updates
Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)
NCT05431270
Recruiting
This is a first-in-human, Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PT199 (an Anti-CD73 mAb) alone and in combination with a PD-1 inhibitor, in patients with locally advanced or metastatic solid tumors that have progressed after all available standard therapy or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Tranquility Research, Webster, Texas
Conditions: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
NCT04173273
Recruiting
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Exten... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/07/2024
Locations: GI Alliance Webster, Webster, Texas
Conditions: Crohn's Disease
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571
Recruiting
The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Webster, Texas
Conditions: NASH/MASH, NAFLD/MASLD
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2024
Locations: Akero Clinical Study Site, Webster, Texas
Conditions: NASH With Fibrosis, MASH With Fibrosis
Register for Updates
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750
Recruiting
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Center for Clinical Studies, Webster, Texas
Conditions: Prurigo Nodularis
Register for Updates
Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine
NCT05516992
Recruiting
The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Tranquil Clinical Research, Webster, Texas
Conditions: Lumbar Degenerative Disc Disease
Register for Updates
A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)
NCT05403476
Recruiting
The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment). For more information, please visit the trial's website www.adamclinicaltrial.com (only applicable in the US).
Gender:
Male
Ages:
Between 18 years and 50 years
Trial Updated:
05/29/2024
Locations: Ferring investigational site, Webster, Texas
Conditions: Male Idiopathic Infertility
Register for Updates